Figure 1

Investigation based on database in terms of OSCC’s P4HA2 expression and the correlation of the expression with pathological feature, and pathway enrichment of P4HA2. (A, B) Investigation using UALCAN, TIMER, and TCGA databases regarding the expression levels of P4HA2 in OSCC and normal tissues, analyzed separately. In contrast to the results in normal tissues, OSCC tissues exhibited higher P4HA2 expression. (C) We analyzed the potential functions of P4HA2 through the GO database. The data indicated that P4HA2 was notably enriched in the PI3K/AKT signaling pathway. (D) Investigation based on the UALCAN database of P4HA2 levels in relation to clinical stage, pathological grades, and lymph node metastasis. The data indicated that P4HA2 expression correlated closely with clinical stage, pathological grades, and lymph node metastasis. *:p less than 0.05, **:p less than 0.01, ***:p less than 0.001, ****:p less than 0.0001.